GO
Loading...

Bristol-Myers Squibb Co

More

  • Early Glance: Pharmaceuticals companies Monday, 17 Nov 2014 | 10:29 AM ET

    Baxter International Inc. fell$. 14 or. 2 percent, to $71.61. Bristol-Myers Squibb Co. rose$. 22 or. 4 percent, to $58.17. Hospira rose$. 12 or. 2 percent, to $58.40.

  • BUSINESS-NEWS-SCHEDULE AT 2200 GMT / 5 PM ET Sunday, 16 Nov 2014 | 4:46 PM ET

    WASHINGTON- President Barack Obama defends the transparency of his signature healthcare law after a White House adviser on the reform said the law passed, in part, because of the "stupidity" of American voters. ALLERGAN, ACTAVIS NEAR DEAL, ANNOUNCEMENT AS EARLY AS MONDAY. NEW YORK- Allergan nears a deal to merge with Actavis Plc, with an announcement coming as soon as...

  • Nov 16- Chemotherapy as a treatment for advanced melanoma could soon become obsolete, researchers said on Sunday, after patients taking an experimental immuno-oncology drug from Bristol-Myers Squibb Co had a much higher survival rate and had other favorable results. Georgina Long, an associate professor at the Melanoma Institute Australia who helped lead...

  • Final Glance: Pharmaceuticals companies Friday, 14 Nov 2014 | 6:03 PM ET

    Baxter International Inc. fell$. 33 or. 5 percent, to $71.75. Bristol-Myers Squibb Co. rose$. 15 or. 3 percent, to $57.95. Hospira rose$. 19 or. 3 percent, to $58.28.

  • Midday Glance: Pharmaceuticals companies Friday, 14 Nov 2014 | 1:17 PM ET

    Baxter International Inc. fell$. 31 or. 4 percent, to $71.77. Bristol-Myers Squibb Co. fell$. 03 or. 1 percent, to $57.77. Hospira fell$. 08 or. 1 percent, to $58.01.

  • Early Glance: Pharmaceuticals companies Friday, 14 Nov 2014 | 10:47 AM ET

    Baxter International Inc. fell$. 54 or. 7 percent, to $71.54. Bristol-Myers Squibb Co. fell$. 32 or. 6 percent, to $57.48. Johnson& Johnson fell$. 32 or. 3 percent, to $108.75.

  • Final Glance: Pharmaceuticals companies Thursday, 13 Nov 2014 | 6:05 PM ET

    Baxter International Inc. rose$. 75 or 1.1 percent, to $72.08. Bristol-Myers Squibb Co. fell$. 81 or 1.4 percent, to $57.80. Johnson& Johnson rose$. 32 or. 3 percent, to $109.07.

  • Midday Glance: Pharmaceuticals companies Thursday, 13 Nov 2014 | 1:28 PM ET

    Baxter International Inc. rose$. 69 or 1.0 percent, to $72.02. Bristol-Myers Squibb Co. fell$. 77 or 1.3 percent, to $57.84. Hospira fell$. 25 or. 4 percent, to $57.85.

  • Early Glance: Pharmaceuticals companies Thursday, 13 Nov 2014 | 12:16 PM ET

    Baxter International Inc. rose$. 62 or. 9 percent, to $71.95. Bristol-Myers Squibb Co. fell$. 67 or 1.1 percent, to $57.94. Hospira rose$. 06 or. 1 percent, to $58.15.

  • LONDON, Nov 13- AstraZeneca is developing an antibody treatment to reverse the blood-thinning effect of its heart drug Brilinta in rare emergency situations, such as urgent surgery or in the event of major bleeding. AstraZeneca said on Thursday the experimental antibody product, MEDI2452, was in pre-clinical tests at its MedImmune biotech unit.

  • Final Glance: Pharmaceuticals companies Wednesday, 12 Nov 2014 | 6:02 PM ET

    Baxter International Inc. rose$. 57 or. 8 percent, to $71.33. Bristol-Myers Squibb Co. fell$. 11 or. 2 percent, to $58.61. Hospira rose$. 78 or 1.4 percent, to $58.09.

  • Midday Glance: Pharmaceuticals companies Wednesday, 12 Nov 2014 | 1:23 PM ET

    Baxter International Inc. rose$. 24 or. 3 percent, to $71.00. Bristol-Myers Squibb Co. fell$. 05 or. 1 percent, to $58.67. Johnson& Johnson fell$. 05 or percent, to $108.86.

  • Early Glance: Pharmaceuticals companies Wednesday, 12 Nov 2014 | 11:05 AM ET

    Baxter International Inc. rose$. 09 or. 1 percent, to $70.85. Bristol-Myers Squibb Co. rose$. 05 or. 1 percent, to $58.77. Pfizer rose$. 17 or. 6 percent, to $30.49.

  • LONDON, Nov 6- AstraZeneca, which saw off a $118 billion bid from Pfizer in May, said quarterly results showed its standalone strength, while recent U.S. tax changes removed much of the case for a new takeover attempt. Chief Executive Pascal Soriot, who has fought hard to prove AstraZeneca does not need the kind of mega-merger offered by Pfizer, said he would use the...

  • LONDON, Nov 6- AstraZeneca raised its 2014 sales forecast for the second quarter in a row on Thursday, as the delayed arrival of generic copies of its Nexium drug in the United States kept cash flowing from the heartburn and ulcer pill. Britain's second biggest drugmaker, which saw off a $118 billion takeover bid from Pfizer in May, now expects revenue to grow in low...

  • LONDON, Nov 6- AstraZeneca raised its 2014 sales forecast for the second quarter in a row on Thursday, as the delayed arrival of Nexium generics in the United States kept cash flowing from the heartburn and ulcer pill. Britain's second biggest drugmaker, which saw off a $118 billion takeover approach from Pfizer in May, now expects revenue to grow slightly this...

  • Midday movers: Aetna, Geron, Loews & more Monday, 3 Nov 2014 | 12:56 PM ET

    Some of Monday's midday movers:

  • Behind the big bearish bet on Bristol-Myers Friday, 31 Oct 2014 | 7:55 AM ET
    File photo: a researcher in a Bristol-Myers Squibb laboratory.

    Shares of Bristol-Myers hit a 13-year high on Thursday. So why was one big trader getting bearish?

  • Cramer Remix: Apologies owed on Wall Street Thursday, 30 Oct 2014 | 7:49 PM ET

    Even after a big move from the Fed, "Mad Money" host Jim Cramer thinks there are some apologies owed to investors.

  • UPDATE 1-FDA panel backs Daiichi's blood thinner Thursday, 30 Oct 2014 | 6:57 PM ET

    Oct 30- A panel of advisers to the U.S. Food and Drug Administration voted 9-1 in favor of approving Japanese drugmaker Daiichi Sankyo Co's blood thinner for use in some patients with atrial fibrillation. According to late-stage trial data submitted by Daiichi, the drug is as effective- and safer than- warfarin, an anticoagulant that has been on the market for more...